- We have updated the Level 1 annotation of ERBB2 Tyrosine Kinase Domain activating mutations in NSCLC (in association with zongertinib) to exclude the following mutations, which fall outside the TKD (ERBB2 V697L, Q709L, A710V and E717D)
- Updated Therapeutic Implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)

| Level | Gene  | Mutation                                                                                     | Cancer Type                | Level-Associated Drug(s) in OncoKB™                                                                                                                                                              | Drug(s) Added to OncoKB™                   | Evidence                                                                                                                     |
| :---- | :---- | :------------------------------------------------------------------------------------------- | :------------------------- | :----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :----------------------------------------- | :--------------------------------------------------------------------------------------------------------------------------- |
| 2     | ERBB2 | Oncogenic Mutations (excluding select TKD activating mutations, which are currently Level 1) | Non-Small Cell Lung Cancer | Trastuzumab Deruxtecan (Level 1\)<br></br><br></br>Ado-Trastuzumab Emtansine (Level 2\)<br></br><br></br>Neratinib, Sevabertinib, Trastuzumab \+ Pertuzumab \+ Docetaxel, Zongertinib (Level 3A) | Zongertinib (Level 2, previously Level 3A) | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V8.2025; PMID: [40293180](https://pubmed.ncbi.nlm.nih.gov/40293180/) |

- Addition of 5 new genes:
  - OGT
  - OGA
  - RSPO2
  - RSPO3
  - VEGFB
